Thrivent Financial for Lutherans Raises Stake in Arcus Biosciences, Inc. $RCUS

Posted by George Bondi on May 27th, 2026

Thrivent Financial for Lutherans raised its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 61.1% during the 4th quarter, Holdings Channel.com reports. The firm owned 80,393 shares of the company’s stock after purchasing an additional 30,484 shares during the period. Thrivent Financial for Lutherans’ holdings in Arcus Biosciences were worth $1,916,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in Arcus Biosciences by 20.1% during the fourth quarter. Vanguard Group Inc. now owns 7,962,874 shares of the company’s stock valued at $189,755,000 after purchasing an additional 1,333,421 shares in the last quarter. Bank of America Corp DE lifted its holdings in Arcus Biosciences by 173.5% during the third quarter. Bank of America Corp DE now owns 1,360,781 shares of the company’s stock valued at $18,507,000 after purchasing an additional 863,162 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Arcus Biosciences by 35.3% during the third quarter. Wellington Management Group LLP now owns 1,266,289 shares of the company’s stock valued at $17,222,000 after purchasing an additional 330,268 shares in the last quarter. Sofinnova Investments Inc. lifted its holdings in Arcus Biosciences by 17.2% during the second quarter. Sofinnova Investments Inc. now owns 1,216,016 shares of the company’s stock valued at $9,898,000 after purchasing an additional 178,240 shares in the last quarter. Finally, Millennium Management LLC lifted its holdings in Arcus Biosciences by 29.2% during the first quarter. Millennium Management LLC now owns 1,194,622 shares of the company’s stock valued at $9,378,000 after purchasing an additional 270,253 shares in the last quarter. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Leerink Partners set a $47.00 price target on shares of Arcus Biosciences in a report on Monday, April 20th. The Goldman Sachs Group boosted their target price on shares of Arcus Biosciences from $30.00 to $34.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Citigroup boosted their target price on shares of Arcus Biosciences from $44.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcus Biosciences in a report on Monday, April 20th. Finally, Truist Financial initiated coverage on shares of Arcus Biosciences in a report on Monday, May 18th. They issued a “buy” rating and a $35.00 target price on the stock. Seven analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $33.89.

View Our Latest Stock Analysis on Arcus Biosciences

Arcus Biosciences Price Performance

Arcus Biosciences stock opened at $24.17 on Wednesday. The company has a market cap of $3.04 billion, a price-to-earnings ratio of -7.60 and a beta of 0.87. The firm’s fifty day moving average is $23.41 and its 200 day moving average is $22.58. The company has a quick ratio of 4.04, a current ratio of 4.04 and a debt-to-equity ratio of 0.19. Arcus Biosciences, Inc. has a 52-week low of $7.91 and a 52-week high of $28.72.

Arcus Biosciences (NYSE:RCUS – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.10). The business had revenue of $17.00 million for the quarter, compared to analysts’ expectations of $29.49 million. Arcus Biosciences had a negative net margin of 156.36% and a negative return on equity of 68.97%. Arcus Biosciences’s revenue for the quarter was down 39.3% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.14) EPS. Sell-side analysts forecast that Arcus Biosciences, Inc. will post -3.54 EPS for the current fiscal year.

Insider Transactions at Arcus Biosciences

In related news, CFO Robert C. Goeltz II sold 7,763 shares of the company’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $25.63, for a total transaction of $198,965.69. Following the sale, the chief financial officer owned 84,161 shares of the company’s stock, valued at $2,157,046.43. This represents a 8.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.60% of the stock is currently owned by insiders.

Arcus Biosciences Profile

(Free Report)

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.